XT
AVDL

XTX Topco’s Avadel Pharmaceuticals AVDL Stock Holding History

XTX Topco’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,039
Closed -$475K – 3834
2025
Q4 		$475K Sell
22,039
-16,481
-43% -$320K 0.01% 1650
2025
Q3 		$588K Buy
+38,520
New +$501K 0.03% 955
2025
Q2 		– Sell
-50,988
Closed -$399K – 2347
2025
Q1 		$399K Buy
50,988
+24,506
+93% +$205K 0.02% 1192
2024
Q4 		$278K Sell
26,482
-22,479
-46% -$273K 0.02% 1292
2024
Q3 		$642K Buy
+48,961
New +$746K 0.05% 647
2022
Q3 		– Sell
-13,093
Closed -$32K – 1098
2022
Q2 		$32K Buy
+13,093
New +$53.8K 0.01% 787
2022
Q1 		– Sell
-11,788
Closed -$95K – 672
2021
Q4 		$95K Buy
+11,788
New +$108K 0.05% 472

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

XTX Topco's AVDL Position: Q1 2026 in Review

XTX Topco sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 22,039 shares — an estimated $475K sold.

XTX Topco first reported a position in AVDL in Q4 2021 and held it in 7 quarters. The position peaked at $642K in Q3 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • XTX Topco reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 22,039 Avadel Pharmaceuticals shares in Q1 2026, an estimated $475K.
  • XTX Topco first reported a position in Avadel Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • XTX Topco's Avadel Pharmaceuticals position peaked at $642K in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.